Principal Investigator
Xiequn Chen, M.D.
Xi'an No.3 Hospital
Total Trials
1
As PI
1
Completed
0
h-index
N/A
Publications
0
Years Active
0
Research Impact
h-index
N/A
Research impact score
Publications
0
Total publications
Trial Results
0
Published trial results
Citations
0
Total citations
Drug Portfolio
DRUG(1)
1 unique interventions1 categories
Analytics
Trial Phases
Phase 11
Trial Status
Recruiting1
Role Distribution
Principal Investigator1
PI Rate100%
Activity Timeline
Clinical Trials (1)
Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma(MM)
PrincipalinvestigatorStart date: 2024-10-03
Research Network
Collaboration Network
1 collaborators·0 connections
Network Legend
KOL
Current InvestigatorCO
High-influence CollaboratorCO
CollaboratorClick: view details
Double-click: go to profile
Drag: move node
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Xi'an No.3 Hospital
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
2 similar investigators found
Lugui Qiu, MD
Institute of Hematology & Blood Diseases Hospital, China
2 trials
Shared therapeutic areas:
Relapsed/Refractory Multiple Myeloma(MM)
Similarity Score30%
Yanjie He
Zhujiang Hospital
2 trials
Shared therapeutic areas:
Relapsed/Refractory Multiple Myeloma(MM)
Similarity Score30%
Publications (0)
No publications found for this investigator.
Clinical Trials (1)
Showing 1 of 1 trials
Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma(MM)
All 1 trials loaded